查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086157

孤兒藥市場：2026-2032年全球市場預測（依治療領域、產品類型、給藥途徑、病患類型、支付者、分銷管道和最終用戶分類）

Orphan Drugs Market by Therapeutic Area, Product Type, Administration Route, Patient Type, Payer Type, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，孤兒藥市場將成長至 4,213.2 億美元，年複合成長率為 11.96%。

主要市場統計數據
基準年 2025 1909.7億美元
預計年份：2026年 2134.5億美元
預測年份 2032 4213.2億美元
複合年成長率 (%) 11.96%

隨著各國政府、監管機構、生物製藥公司、醫療系統和病患團體加強應對醫療需求未被滿足的罕見疾病，孤兒藥市場正不斷擴大。據估計，全球約有3億人患有罕見疾病，其中美國約有3,000萬人，迄今已發現超過7,000種罕見疾病。儘管科學取得了進步，但廣泛引用的公共衛生統計數據顯示，約95%的罕見疾病仍然缺乏核准的治療方法，這在孤兒藥的發現和開發方面造成了持續的創新缺口。

這些發展得益於既有的激勵機制，例如美國的《孤兒藥法案》（適用於影響人數少於20萬的疾病）和歐盟的孤兒藥認客製化度（針對每萬人口中影響人數少於5人的危及生命或慢性致殘性疾病）。這些政策，加上特定司法管轄區的獎勵獨佔權、稅額扣抵和費用減免、快速核准流程以及生物標記科學的進步，確保孤兒藥在全球製藥業中繼續保持重要的戰略地位。

孤兒藥領域的變革性變化

孤兒藥的模式正從傳統的小分子化合物和酵素替代療法轉向精準生物製劑、基因療法、RNA藥物和細胞療法。基因組學、新生兒篩檢、自然史研究和真實世界數據（REW）的進步改進了疾病識別和臨床試驗設計，使申辦方能夠針對小規模、更精準的患者群體進行研究，並設定更清晰的臨床終點。

人工智慧對孤兒藥的累積影響

人工智慧 (AI) 透過改進標靶辨識、表現型匹配、文獻挖掘、蛋白質建模和藥物重定位，加速了孤兒藥的發現。在罕見疾病研究中，資料集通常分散且患者群體規模小規模，因此，人工智慧驅動的分析可以將基因組突變、臨床病史、影像學和登記資料關聯起來，從而揭示原本難以發現的疾病機制。

主要區域洞察：亞太地區、北美地區、拉丁美洲地區、歐洲地區、中東和非洲地區

北美在孤兒藥創新領域仍處於領先地位，這得益於美國食品藥物管理局（FDA）成熟的認定框架、雄厚的生物醫學資金、大學附屬醫療中心、完善的臨床試驗基礎設施以及成熟的患者支持網路。尤其值得一提的是，美國在孤兒病政策、監管科學、臨床開發和醫保報銷等方面的討論中發揮著舉足輕重的主導，而加拿大則透過國家政策舉措、衛生技術評估和省級醫保報銷機制，持續加強孤兒病治療的可及性。

來自主要組織（東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約）的見解

東協市場正崛起為孤兒藥取得和診斷的關鍵新興市場，新加坡、泰國、馬來西亞、印尼、越南和菲律賓在孤兒藥取得和診斷的關鍵新興市場，新加坡、泰國、馬來西亞、印尼、越南和菲律賓在孤兒病政策發展方面均處於不同階段。基因組醫學能力建設的提升、專科醫療中心的建立、新生兒篩檢計畫的開展以及跨境臨床合作的加強，都為該地區的進展提供了支持。然而，對於中低收入國家而言，確保統一且負擔得起的保險報銷仍然是一項重大挑戰。

主要孤兒藥市場的關鍵國家洞察

美國憑藉FDA的獎勵、對生物醫學領域的大力投資、先進的研究型醫院、臨床試驗網路以及大規模的罕見疾病支持體系，在全球孤兒藥商業化過程中處於領先地位。加拿大是孤兒藥准入的關鍵市場，擁有集中化的醫療技術評估系統和省級醫保報銷機制。同時，墨西哥和巴西作為拉丁美洲的主要國家，其監管現代化、公共採購、專科醫療中心以及公私合營的專科醫療網路正在推動孤兒藥的推廣應用。

為孤兒藥產業領導者提供的實用建議

產業領導者應優先考慮在 III 期臨床試驗之前啟動的證據策略，包括自然史研究、患者登記、檢驗的生物標記、患者報告結局和真實世界數據項目。這些資源有助於加強與監管機構的溝通，支持衛生技術評估，並加強與支付方在患者群體較小、隨機試驗數據可能有限的適應症領域的談判。

調查方法

本執行摘要採用系統的二手研究途徑編寫，重點關注經檢驗的公共領域和行業認可的資訊來源。主要資訊來源包括美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 的監管定義和指南、公共衛生機構和患者權益倡導團體提供的罕見病患病率參考資料，以及國家監管機構、保險報銷機構和衛生技術評估組織的政策資訊。

結論

科學創新，加上監管獎勵、患者支持活動以及全球對罕見疾病負擔日益成長的認知，預計將繼續佔據重要的戰略地位。基因組學、人工智慧驅動的藥物研發、先進療法和真實世界數據相結合，預計將為那些治療選擇有限或尚未獲得批准療法的疾病帶來最大的機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：孤兒藥市場：依治療領域分類

  • 免疫學
  • 感染疾病
  • 代謝性疾病
  • 神經病學
  • 腫瘤學

第8章：孤兒藥市場：依產品類型分類

  • 生物製劑
    • 酵素
    • 單株抗體
    • 重組蛋白
  • 基因治療
    • 非病毒載體
    • 病毒載體
  • 低分子化合物
  • 組織治療

第9章：孤兒藥市場：依給藥途徑分類

  • 吸入
  • 注射藥物
    • 肌肉內部
    • 靜脈
    • 皮下
  • 口服
  • 外用

第10章：孤兒藥市場：依病患類型分類

  • 成人
  • 兒童
  • 老年人

第11章：孤兒藥市場：以支付方分類

  • 政府項目
  • 自費
  • 私人保險

第12章：孤兒藥市場：依通路分類

  • 離線
  • 線上

第13章：孤兒藥市場：依最終用戶分類

  • 醫院
  • 專科診所
  • 研究機構
  • 居家照護環境

第14章：孤兒藥市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：孤兒藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 孤兒藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • AbbVie Inc
  • Alexion Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • Amgen Inc
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Bayer AG
  • BioMarin Pharmaceutical Inc
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Co Ltd
  • F. Hoffmann-La Roche Ltd
  • FGK Clinical Research GmbH
  • Gilead Sciences Inc
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Ipsen Pharma
  • Johnson & Johnson Services Inc
  • Kyowa Kirin Co Ltd
  • Novartis AG
  • Novo Nordisk AS
  • Pfizer Inc
  • Recordati SpA
  • Regeneron Pharmaceuticals Inc
  • Sanofi SA
  • Sarepta Therapeutics Inc
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • UCB SA
  • Ultragenyx Pharmaceutical Inc
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-036C5CF3B4B9

The Orphan Drugs Market is projected to grow by USD 421.32 billion at a CAGR of 11.96% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 190.97 billion
Estimated Year [2026] USD 213.45 billion
Forecast Year [2032] USD 421.32 billion
CAGR (%) 11.96%

The orphan drugs market is expanding as governments, regulators, biopharmaceutical developers, healthcare systems, and patient organizations intensify efforts to address rare diseases with high unmet medical need. Rare diseases collectively affect an estimated 300 million people worldwide, including about 30 million people in the United States, while more than 7,000 rare diseases have been identified. Despite scientific progress, widely cited public health estimates indicate that approximately 95% of rare diseases still lack an approved treatment, creating a durable innovation gap for orphan drug discovery and development.

Momentum is supported by established incentive frameworks such as the U.S. Orphan Drug Act, which applies to conditions affecting fewer than 200,000 people in the United States, and the European Union orphan designation pathway for life-threatening or chronically debilitating diseases affecting no more than 5 in 10,000 people. These policies, combined with regulatory exclusivity, tax credits or fee reductions in select jurisdictions, accelerated pathways, and stronger biomarker science, continue to make orphan drugs a strategically important segment of the global pharmaceutical industry.

Transformative Shifts in the Orphan Drug Landscape

The orphan drugs landscape is shifting from traditional small-molecule and enzyme replacement approaches toward precision biologics, gene therapies, RNA-based medicines, and cell-based interventions. Advances in genomics, newborn screening, natural history studies, and real-world evidence are improving disease identification and trial design, enabling sponsors to pursue smaller but more targeted patient populations with clearer clinical endpoints.

Commercial models are also changing. Orphan drugs often serve limited populations, but development programs face complex manufacturing, evidence-generation, access, and reimbursement requirements. Payers are increasingly demanding outcomes-based evidence, long-term durability data, and transparent value justification, particularly for one-time or high-cost therapies. At the same time, patient advocacy groups are becoming central partners in registries, trial recruitment, endpoint selection, and post-approval evidence generation.

Regulatory agencies are placing greater emphasis on confirmatory studies, safety surveillance, and clinically meaningful benefit. As a result, successful participants in orphan drug development are integrating regulatory strategy, health economics, patient engagement, and global access planning much earlier in the product lifecycle.

Cumulative Impact of Artificial Intelligence on Orphan Drugs

Artificial intelligence is accelerating orphan drug discovery by improving target identification, phenotype matching, literature mining, protein modeling, and drug repurposing. Because rare disease research often suffers from fragmented datasets and small patient cohorts, AI-enabled analytics can help connect genomic variants, clinical histories, imaging, and registry data to reveal disease mechanisms that may otherwise remain hidden.

AI is also influencing clinical development. Machine learning models support patient stratification, site selection, synthetic control arm design, and real-world evidence analysis, helping reduce trial delays in ultra-rare indications. In diagnosis, AI-enabled clinical decision support and natural language processing can shorten the diagnostic odyssey by flagging rare disease patterns across electronic health records, claims data, and laboratory findings.

The impact is cumulative rather than isolated: each improvement in diagnosis, data integration, trial design, and post-market monitoring strengthens the evidence ecosystem. However, industry leaders must address bias, data privacy, interoperability, explainability, and regulatory validation to ensure AI-driven orphan drug development remains scientifically credible and patient-centered.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

North America remains a leading region for orphan drug innovation, supported by the U.S. Food and Drug Administration's mature designation framework, deep biomedical financing, academic medical centers, clinical trial infrastructure, and established patient advocacy networks. The United States is particularly influential in rare disease policy, regulatory science, clinical development, and reimbursement discussions, while Canada continues to strengthen rare disease access through national policy initiatives, health technology assessment, and provincial reimbursement mechanisms.

Europe is defined by coordinated regulation, advanced health technology assessment systems, and the European Medicines Agency's orphan designation pathway. The European Union provides scientific advice, protocol assistance, and market exclusivity incentives, although country-by-country pricing and reimbursement decisions can create access variability. The United Kingdom, Germany, France, Italy, and Spain remain important rare disease markets due to specialist centers, registry activity, and established assessment systems. Russia has designated rare disease funding mechanisms in select areas, but access is shaped by procurement policy, reimbursement constraints, and geopolitical complexity.

Asia-Pacific is gaining importance as Japan, China, South Korea, Australia, and India expand rare disease policies, genetic testing capacity, clinical research infrastructure, and expedited review pathways. Japan has a long-standing orphan drug framework, China has introduced rare disease lists and priority review mechanisms, South Korea supports advanced biopharma innovation, Australia benefits from mature regulatory standards, and India's national rare disease policy has increased public attention to affordability and diagnosis. Latin America, the Middle East, and Africa present meaningful long-term opportunities but face uneven diagnostic capacity, reimbursement constraints, and limited specialist access. Brazil and Mexico are important Latin American markets, GCC countries are investing in specialty care and genomics, and African markets increasingly rely on public health partnerships, newborn screening expansion, donor-supported diagnostics, and regional centers of excellence to improve rare disease care.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are emerging as important access and diagnosis frontiers for orphan drugs, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines at different stages of rare disease policy development. Regional progress is supported by growing genomic medicine capacity, specialist centers, newborn screening programs, and cross-border clinical collaboration, although reimbursement consistency and affordability remain major challenges across lower- and middle-income settings.

The GCC is investing in precision medicine, national genome programs, and specialty hospital infrastructure, which is highly relevant given the higher observed burden of some inherited disorders in populations with consanguinity. The European Union remains a benchmark for orphan designation, coordinated scientific assessment, European reference networks, and rare disease policy collaboration, while also facing increasing pressure to balance innovation incentives with affordability, equitable access, and evidence requirements for advanced therapies.

BRICS countries represent large patient populations and expanding clinical trial potential, but access depends on local regulatory modernization, domestic manufacturing priorities, public reimbursement design, and the availability of genetic testing. G7 countries continue to shape global orphan drug policy, pricing expectations, health technology assessment standards, and evidence generation norms through mature regulatory agencies and advanced biomedical research systems. NATO membership is not a health-market category, yet many NATO countries are high-income economies with strong biomedical systems that support rare disease research, preparedness, medicine security, and resilient pharmaceutical supply chains.

Key Country Insights for Major Orphan Drug Markets

The United States leads global orphan drug commercialization through FDA incentives, strong biomedical investment, advanced research hospitals, clinical trial networks, and a large rare disease advocacy ecosystem. Canada offers an important access market with centralized health technology assessment and provincial reimbursement dynamics, while Mexico and Brazil are key Latin American countries where regulatory modernization, public procurement, specialist centers, and public-private specialty care networks influence orphan drug uptake.

In Europe, the United Kingdom combines strong genomics assets, the National Health Service, and health technology assessment through national reimbursement processes. Germany remains an important early-launch market due to its structured reimbursement pathway, while France, Italy, and Spain provide significant patient populations and specialist care networks but require robust clinical and economic evidence. Russia has rare disease reimbursement programs in select areas, though market access is affected by policy, procurement, localization requirements, and geopolitical complexity.

In Asia-Pacific, China is rapidly expanding rare disease lists, priority review mechanisms, clinical research activity, and domestic innovation, while India offers a large genetic disease burden and improving policy attention but faces affordability, diagnostic, and reimbursement barriers. Japan has a mature orphan drug system supported by established regulatory incentives and specialist care, South Korea supports advanced biopharma innovation and expedited pathways, and Australia combines strong regulatory standards with growing rare disease policy coordination, newborn screening activity, patient registries, and specialist care infrastructure.

Actionable Recommendations for Orphan Drug Industry Leaders

Industry leaders should prioritize evidence strategies that begin before pivotal trials, including natural history studies, patient registries, validated biomarkers, patient-reported outcomes, and real-world evidence plans. These assets improve regulatory dialogue, support health technology assessment, and strengthen payer negotiations in small-population indications where randomized trial data may be limited.

Organizations should also build patient-centered development models by partnering with advocacy groups, reducing trial burden, improving genetic testing access, enabling decentralized trial components where appropriate, and aligning endpoints with outcomes that matter to patients and caregivers. For advanced therapies, manufacturers must prepare scalable quality systems, cold-chain logistics, long-term follow-up protocols, pharmacovigilance plans, and clear durability evidence.

Commercial success will increasingly depend on integrated global access planning. Leaders should evaluate value-based agreements, managed entry models, early access programs, differential access pathways, and country-specific reimbursement evidence. Strategic use of AI should focus on explainable, validated applications in diagnosis, trial recruitment, pharmacovigilance, and portfolio prioritization, with strong governance for privacy, bias mitigation, data provenance, and data quality.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified public-domain and industry-recognized sources. Core inputs include regulatory definitions and guidance from the U.S. Food and Drug Administration and European Medicines Agency, rare disease prevalence references from public health and patient advocacy organizations, and policy information from national regulatory, reimbursement, and health technology assessment agencies.

The methodology applies triangulation across regulatory documents, peer-reviewed literature, clinical trial databases, health technology assessment frameworks, public disclosures, and credible rare disease organizations. Market interpretation emphasizes data-backed signals such as orphan designation criteria, prevalence thresholds, treatment gaps, regulatory incentives, clinical development trends, evidence requirements, and regional access conditions.

Insights are synthesized through an executive-summary lens that evaluates market structure, innovation drivers, policy dynamics, geographic opportunity, and strategic implications. The analysis avoids unsupported projections and focuses on verifiable factors shaping orphan drug discovery, development, approval, reimbursement, and patient access.

Conclusion

The orphan drugs market is positioned for sustained strategic relevance as scientific innovation converges with regulatory incentives, patient advocacy, and growing global recognition of rare disease burden. The strongest opportunities are emerging where genomics, AI-enabled discovery, advanced therapies, and real-world evidence combine to address conditions with limited or no approved treatment options.

However, the market is also entering a more demanding phase. Payers and regulators are seeking stronger evidence of clinical benefit, durability, safety, and value, especially for high-cost and potentially curative therapies. Organizations that can integrate patient insight, rigorous data generation, manufacturing readiness, and access planning from the earliest stages will be best positioned to succeed.

In this environment, orphan drug leadership will depend not only on breakthrough science but also on equitable diagnosis, credible evidence, responsible pricing, and cross-stakeholder collaboration that turns rare disease innovation into measurable patient impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Orphan Drugs Market, by Therapeutic Area

  • 7.1. Immunology
  • 7.2. Infectious Diseases
  • 7.3. Metabolic Disorders
  • 7.4. Neurology
  • 7.5. Oncology

8. Orphan Drugs Market, by Product Type

  • 8.1. Biologics
    • 8.1.1. Enzymes
    • 8.1.2. Monoclonal Antibodies
    • 8.1.3. Recombinant Proteins
  • 8.2. Gene Therapy
    • 8.2.1. Non-Viral Vector
    • 8.2.2. Viral Vector
  • 8.3. Small-Molecule
  • 8.4. Tissue Therapy

9. Orphan Drugs Market, by Administration Route

  • 9.1. Inhalation
  • 9.2. Injectable
    • 9.2.1. Intramuscular
    • 9.2.2. Intravenous
    • 9.2.3. Subcutaneous
  • 9.3. Oral
  • 9.4. Topical

10. Orphan Drugs Market, by Patient Type

  • 10.1. Adult
  • 10.2. Pediatric
  • 10.3. Geriatric

11. Orphan Drugs Market, by Payer Type

  • 11.1. Government Programs
  • 11.2. Out-Of-Pocket
  • 11.3. Private Insurance

12. Orphan Drugs Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Orphan Drugs Market, by End User

  • 13.1. Hospitals
  • 13.2. Specialty Clinics
  • 13.3. Research Institutes
  • 13.4. Homecare Settings

14. Orphan Drugs Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Orphan Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Orphan Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. AbbVie Inc
  • 18.2. Alexion Pharmaceuticals Inc
  • 18.3. Alnylam Pharmaceuticals Inc
  • 18.4. Amgen Inc
  • 18.5. Astellas Pharma Inc
  • 18.6. AstraZeneca PLC
  • 18.7. Bayer AG
  • 18.8. BioMarin Pharmaceutical Inc
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. Daiichi Sankyo Co Ltd
  • 18.11. F. Hoffmann-La Roche Ltd
  • 18.12. FGK Clinical Research GmbH
  • 18.13. Gilead Sciences Inc
  • 18.14. GlaxoSmithKline PLC
  • 18.15. Incyte Corporation
  • 18.16. Ipsen Pharma
  • 18.17. Johnson & Johnson Services Inc
  • 18.18. Kyowa Kirin Co Ltd
  • 18.19. Novartis AG
  • 18.20. Novo Nordisk AS
  • 18.21. Pfizer Inc
  • 18.22. Recordati SpA
  • 18.23. Regeneron Pharmaceuticals Inc
  • 18.24. Sanofi SA
  • 18.25. Sarepta Therapeutics Inc
  • 18.26. Swedish Orphan Biovitrum AB
  • 18.27. Takeda Pharmaceutical Company Limited
  • 18.28. UCB SA
  • 18.29. Ultragenyx Pharmaceutical Inc
  • 18.30. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORPHAN DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ORPHAN DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ORPHAN DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ORPHAN DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORPHAN DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ORPHAN DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ORPHAN DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ORPHAN DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ORPHAN DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ORPHAN DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMMUNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENZYMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENZYMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENZYMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NON-VIRAL VECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-VIRAL VECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NON-VIRAL VECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VIRAL VECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VIRAL VECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VIRAL VECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SMALL-MOLECULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SMALL-MOLECULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SMALL-MOLECULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TISSUE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TISSUE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TISSUE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GOVERNMENT PROGRAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GOVERNMENT PROGRAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GOVERNMENT PROGRAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OUT-OF-POCKET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OUT-OF-POCKET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OUT-OF-POCKET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PRIVATE INSURANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PRIVATE INSURANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PRIVATE INSURANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ORPHAN DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 191. GCC ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. GCC ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 194. GCC ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. GCC ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. GCC ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. G7 ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. G7 ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 222. G7 ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. G7 ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 224. G7 ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. G7 ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 227. G7 ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. G7 ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. G7 ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. NATO ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. NATO ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 233. NATO ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. NATO ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 235. NATO ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. NATO ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 237. NATO ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. NATO ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. NATO ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CANADA ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. CANADA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 256. CANADA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. CANADA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 258. CANADA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 259. CANADA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 260. CANADA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 261. CANADA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. CANADA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. CANADA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. CANADA ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. MEXICO ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. MEXICO ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 267. MEXICO ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. MEXICO ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 269. MEXICO ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 270. MEXICO ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 271. MEXICO ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 272. MEXICO ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. MEXICO ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. MEXICO ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. MEXICO ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. BRAZIL ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. BRAZIL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 278. BRAZIL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. BRAZIL ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 280. BRAZIL ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. BRAZIL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 282. BRAZIL ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 283. BRAZIL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. BRAZIL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. BRAZIL ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. GERMANY ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. GERMANY ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 300. GERMANY ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. GERMANY ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 302. GERMANY ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 303. GERMANY ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 304. GERMANY ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 305. GERMANY ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. GERMANY ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. GERMANY ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 308. GERMANY ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. FRANCE ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 310. FRANCE ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 311. FRANCE ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. FRANCE ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 313. FRANCE ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 314. FRANCE ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 315. FRANCE ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 316. FRANCE ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. FRANCE ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. FRANCE ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 319. FRANCE ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 320. RUSSIA ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 321. RUSSIA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 322. RUSSIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. RUSSIA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 324. RUSSIA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 325. RUSSIA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 326. RUSSIA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 327. RUSSIA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. RUSSIA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. RUSSIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 330. RUSSIA ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 331. ITALY ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 332. ITALY ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 333. ITALY ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. ITALY ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 335. ITALY ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 336. ITALY ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 337. ITALY ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 338. ITALY ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 339. ITALY ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 340. ITALY ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 341. ITALY ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 342. SPAIN ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 343. SPAIN ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 344. SPAIN ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. SPAIN ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 346. SPAIN ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 347. SPAIN ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 348. SPAIN ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 349. SPAIN ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 350. SPAIN ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 351. SPAIN ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 352. SPAIN ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 353. CHINA ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 354. CHINA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 355. CHINA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 356. CHINA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 357. CHINA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 358. CHINA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 359. CHINA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 360. CHINA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 361. CHINA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 362. CHINA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 363. CHINA ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 364. INDIA ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 365. INDIA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 366. INDIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 367. INDIA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 368. INDIA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 369. INDIA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 370. INDIA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 371. INDIA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 372. INDIA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 373. INDIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 374. INDIA ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 375. JAPAN ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 376. JAPAN ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 377. JAPAN ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 378. JAPAN ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 379. JAPAN ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 380. JAPAN ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 381. JAPAN ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 382. JAPAN ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 383. JAPAN ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 384. JAPAN ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 385. JAPAN ORPHAN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 386. AUSTRALIA ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 387. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 388. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 389. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 390. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 391. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 392. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY INJECT